News & Events

Disc Medicine Announces Completion of Merger with Gemini Therapeutics

The combined company will operate as Disc Medicine and will trade on the Nasdaq Global Market under the ticker symbol “IRON” Approximately $175 million of cash and cash equivalents to provide operating runway into 2025 WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) — Disc Medicine, Inc.

More News

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development...

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...